Is Stoke Therapeutics, Inc. overvalued or undervalued?

As of 13 August 2025, the valuation grade for Stoke Therapeutics, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued at this time. Key valuation ratios include a P/E ratio of 12, an EV to EBITDA ratio of 5.94, and a PEG ratio of 0.09, which suggests that the stock may be undervalued relative to its growth potential.
In comparison to its peers, CorMedix, Inc. has a P/E ratio of 18.60, indicating a more favorable valuation, while Taysha Gene Therapies, Inc. shows a negative P/E, reflecting its risky profile. Notably, Stoke Therapeutics has outperformed the S&P 500 year-to-date with a return of 113.06% compared to the index's 12.22%, although it has underperformed over the longer term, particularly in the 5-year and 10-year periods.